Gastrointestinal side-effects after switch to generic valproic acid. 1998

E Sherwood Brown, and E Shellhorn, and T Suppes
Department of Psychiatry, University of Texas-Southwestern Medical Center Dallas, 75235-9070, USA.

UI MeSH Term Description Entries
D005260 Female Females
D005767 Gastrointestinal Diseases Diseases in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Cholera Infantum,Gastrointestinal Disorders,Functional Gastrointestinal Disorders,Gastrointestinal Disorders, Functional,Disease, Gastrointestinal,Diseases, Gastrointestinal,Functional Gastrointestinal Disorder,Gastrointestinal Disease,Gastrointestinal Disorder,Gastrointestinal Disorder, Functional
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic
D013810 Therapeutic Equivalency The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease. Bioequivalence,Clinical Equivalency,Equivalency, Therapeutic,Generic Equivalency,Clinical Equivalencies,Equivalencies, Clinical,Equivalencies, Therapeutic,Equivalency, Clinical,Therapeutic Equivalencies,Bioequivalences,Equivalencies, Generic,Equivalency, Generic,Generic Equivalencies
D014635 Valproic Acid A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS. Dipropyl Acetate,Divalproex,Sodium Valproate,2-Propylpentanoic Acid,Calcium Valproate,Convulsofin,Depakene,Depakine,Depakote,Divalproex Sodium,Ergenyl,Magnesium Valproate,Propylisopropylacetic Acid,Semisodium Valproate,Valproate,Valproate Calcium,Valproate Sodium,Valproic Acid, Sodium Salt (2:1),Vupral,2 Propylpentanoic Acid

Related Publications

E Sherwood Brown, and E Shellhorn, and T Suppes
January 1988, Der Nervenarzt,
E Sherwood Brown, and E Shellhorn, and T Suppes
December 1997, Mental retardation,
E Sherwood Brown, and E Shellhorn, and T Suppes
April 2000, The Journal of clinical psychiatry,
E Sherwood Brown, and E Shellhorn, and T Suppes
March 2010, Psychiatria Danubina,
E Sherwood Brown, and E Shellhorn, and T Suppes
October 2004, The European journal of health economics : HEPAC : health economics in prevention and care,
E Sherwood Brown, and E Shellhorn, and T Suppes
January 1989, The American journal of psychiatry,
E Sherwood Brown, and E Shellhorn, and T Suppes
October 1984, Neurology,
E Sherwood Brown, and E Shellhorn, and T Suppes
March 1986, British journal of clinical pharmacology,
E Sherwood Brown, and E Shellhorn, and T Suppes
March 1998, Orthopedics,
E Sherwood Brown, and E Shellhorn, and T Suppes
April 2007, Journal of clinical psychopharmacology,
Copied contents to your clipboard!